Amedeo Smart

Free Medical Literature Service

 

Amedeo

Head and Neck Cancer
  Free Subscription

Articles published in
J Clin Oncol
    December 2024
  1. NICHOLS AC, Theurer J, Prisman E, Read N, et al
    Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial.
    J Clin Oncol. 2024;42:4023-4028.
    >> Share

    October 2024
  2. SWIECICKI PL, Yilmaz E, Rosenberg AJ, Fujisawa T, et al
    Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.
    J Clin Oncol. 2024 Oct 31:JCO2400646. doi: 10.1200/JCO.24.00646.
    >> Share

  3. TOPKAN E, Somay E, Bascil S, Pehlivan B, et al
    Underrated But Significant Risk Factors of Osteoradionecrosis of the Jaw in Patients With Head and Neck Cancer.
    J Clin Oncol. 2024 Oct 3:JCO2401020. doi: 10.1200/JCO.24.01020.
    >> Share

  4. CHEN WJ, Yu X, Lu YQ, Pfeiffer RM, et al
    Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial.
    J Clin Oncol. 2024 Oct 1:JCO2301296. doi: 10.1200/JCO.23.01296.
    >> Share

    September 2024
  5. WIRTH LJ, Brose MS, Subbiah V, Worden F, et al
    Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
    J Clin Oncol. 2024;42:3187-3195.
    >> Share

    August 2024
  6. GARDEN AS
    Selecting Patients With Oropharyngeal Cancer for Lower Dose Radiation.
    J Clin Oncol. 2024;42:2835-2836.
    >> Share

    July 2024
  7. DZIENIS M, Cundom J, Fuentes CS, Spreafico A, et al
    Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
    J Clin Oncol. 2024 Jul 22:JCO2302625. doi: 10.1200/JCO.23.02625.
    >> Share

  8. XIA C, Li H, Chen W
    Reduction in Esophageal Cancer Incidence and Mortality by Screening Endoscopy.
    J Clin Oncol. 2024 Jul 10:JCO2400557. doi: 10.1200/JCO.24.00557.
    >> Share

    June 2024
  9. HEGEWISCH-BECKER S, Mendez G, Chao J, Nemecek R, et al
    First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
    J Clin Oncol. 2024;42:2080-2093.
    >> Share

  10. HUANG CL, Zhang N, Jiang W, Xie FY, et al
    Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2024;42:2021-2025.
    >> Share

  11. JANJIGIAN YY, Ajani JA, Moehler M, Shen L, et al
    First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    J Clin Oncol. 2024;42:2012-2020.
    >> Share

    May 2024
  12. GILLENWATER AM, Vigneswaran N, Sikora AG
    Assessing the Role of Inflammation in Oral Tongue Carcinogenesis.
    J Clin Oncol. 2024;42:1729-1730.
    >> Share

  13. TIAN Q, Jiang L, Dai D, Liu L, et al
    Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma.
    J Clin Oncol. 2024;42:1754-1765.
    >> Share

  14. TOTA JE, Engels EA, Lingen MW, Agrawal N, et al
    Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals.
    J Clin Oncol. 2024;42:1745-1753.
    >> Share

  15. JIA R, Shan T, Zheng A, Zhang Y, et al
    Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.
    J Clin Oncol. 2024 May 6:JCO2302009. doi: 10.1200/JCO.23.02009.
    >> Share

  16. WATSON E EE, Hueniken K, Lee J, Huang SH, et al
    Development and Standardization of an Osteoradionecrosis Classification System in Head and Neck Cancer: Implementation of a Risk-Based Model.
    J Clin Oncol. 2024 May 1:JCO2301951. doi: 10.1200/JCO.23.01951.
    >> Share

  17. PETERSON DE, Koyfman SA, Yarom N, Lynggaard CD, et al
    Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline.
    J Clin Oncol. 2024 May 1:JCO2302750. doi: 10.1200/JCO.23.02750.
    >> Share

    April 2024
  18. WARDILL HR, Bossi P, Sonis ST
    Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis.
    J Clin Oncol. 2024;42:1436-1438.
    >> Share

  19. PENG X, Li Z, Pei Y, Zheng S, et al
    Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1426-1435.
    >> Share

    March 2024
  20. LEE NY, Sherman EJ, Schoder H, Wray R, et al
    Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.
    J Clin Oncol. 2024;42:940-950.
    >> Share

  21. LIU M, Yang W, Guo C, Liu Z, et al
    Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.
    J Clin Oncol. 2024 Mar 8:JCO2301284. doi: 10.1200/JCO.23.01284.
    >> Share

    February 2024
  22. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    >> Share

    January 2024
  23. SUN R, Liu J, Wei LJ
    Assessing Predictability of Pathologic Lymph Node Regression for Recurrence and Survival in Esophageal Adenocarcinoma.
    J Clin Oncol. 2024;42:366.
    >> Share

    December 2023

  24. Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    J Clin Oncol. 2023 Dec 19:JCO2302629. doi: 10.1200/JCO.23.02629.
    >> Share

    November 2023
  25. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    >> Share

    October 2023
  26. MOORE JL, Green M, Santaolalla A, Deere H, et al
    Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
    J Clin Oncol. 2023;41:4522-4534.
    >> Share

  27. FARON M, Cheugoua-Zanetsie M, Tierney J, Thirion P, et al
    Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
    J Clin Oncol. 2023;41:4535-4547.
    >> Share

    September 2023
  28. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    >> Share

  29. KEAM B, Hong MH, Shin SH, Heo SG, et al
    Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    J Clin Oncol. 2023 Sep 12:JCO2202786. doi: 10.1200/JCO.22.02786.
    >> Share

    August 2023
  30. GILLISON ML
    Flashback Foreword: Chemoradiotherapy for Nasopharyngeal Carcinoma.
    J Clin Oncol. 2023;41:3963-3964.
    >> Share

    July 2023
  31. LOU PJ, Jacky Lam WK, Hsu WL, Pfeiffer RM, et al
    Performance and Operational Feasibility of Epstein-Barr Virus-Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches.
    J Clin Oncol. 2023 Jul 21:JCO2201979. doi: 10.1200/JCO.22.01979.
    >> Share

    June 2023
  32. PARK JH, Hong JY, Shen JJ, Han K, et al
    Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study.
    J Clin Oncol. 2023;41:3363-3373.
    >> Share

  33. KERMORGANT S
    Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer.
    J Clin Oncol. 2023 Jun 15:JCO2300460. doi: 10.1200/JCO.23.00460.
    >> Share

  34. GILLISON ML
    Flashback Foreword: Human Papillomavirus and Incidence and Survival of Oropharyngeal Cancers.
    J Clin Oncol. 2023;41:3079-3080.
    >> Share

    May 2023
  35. EL ZARIF T, Nassar AH, Adib E, Fitzgerald BG, et al
    Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
    J Clin Oncol. 2023 May 16:JCO2202459. doi: 10.1200/JCO.22.02459.
    >> Share

  36. XIE DX, Kut C, Quon H, Seiwert TY, et al
    Clinical Uncertainties of Circulating Tumor DNA in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in the Absence of National Comprehensive Cancer Network Guidelines.
    J Clin Oncol. 2023;41:2483-2487.
    >> Share

    March 2023
  37. YU G, Zhang N, Guan AJ, Qiao YW, et al
    Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1-Expressing Esophageal Squamous Cell Carcinoma.
    J Clin Oncol. 2023 Mar 28:JCO2300057. doi: 10.1200/JCO.23.00057.
    >> Share

  38. BAUMAN JE, Saba NF, Roe D, Bauman JR, et al
    Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
    J Clin Oncol. 2023 Mar 28:JCO2201994. doi: 10.1200/JCO.22.01994.
    >> Share

  39. BURTNESS B
    First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?
    J Clin Oncol. 2023 Mar 6:JCO2202349. doi: 10.1200/JCO.22.02349.
    >> Share

  40. SHAH MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, et al
    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
    J Clin Oncol. 2023;41:1470-1491.
    >> Share

    February 2023
  41. XU H, Zhang Y, Wu H, Zhou N, et al
    High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules.
    J Clin Oncol. 2023;41:1296-1306.
    >> Share

  42. DING X, Zhang WJ, You R, Zou X, et al
    Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
    J Clin Oncol. 2023 Feb 3:JCO2201450. doi: 10.1200/JCO.22.01450.
    >> Share

    January 2023
  43. PATIL VM, Noronha V, Menon N, Singh A, et al
    Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
    J Clin Oncol. 2023 Jan 27:JCO2200980. doi: 10.1200/JCO.22.00980.
    >> Share

  44. MO DC, Huang JF, Luo PH
    Low-Dose Immunotherapy Plus Triple Metronomic Chemotherapy for Head and Neck Cancer.
    J Clin Oncol. 2023 Jan 20:JCO2202398. doi: 10.1200/JCO.22.02398.
    >> Share

    December 2022
  45. HO AL, Foster NR, Zoroufy AJ, Campbell JD, et al
    Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
    J Clin Oncol. 2022;40:4240-4249.
    >> Share

  46. YILMAZ E, Ismaila N, Bauman JE, Dabney R, et al
    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.
    J Clin Oncol. 2022 Dec 15:JCO2202328. doi: 10.1200/JCO.22.02328.
    >> Share

  47. WU HX, Pan YQ, He Y, Wang ZX, et al
    Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
    J Clin Oncol. 2022 Dec 6:JCO2201490. doi: 10.1200/JCO.22.01490.
    >> Share

  48. HADDAD RI, Harrington K, Tahara M, Ferris RL, et al
    Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
    J Clin Oncol. 2022 Dec 6:JCO2200332. doi: 10.1200/JCO.22.00332.
    >> Share

    November 2022
  49. ROBBINS HA, Ferreiro-Iglesias A, Waterboer T, Brenner N, et al
    Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.
    J Clin Oncol. 2022;40:3613-3622.
    >> Share

    October 2022
  50. PATIL VM, Noronha V, Menon N, Rai R, et al
    Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
    J Clin Oncol. 2022 Oct 20:JCO2201015. doi: 10.1200/JCO.22.01015.
    >> Share

  51. HO AL
    Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    J Clin Oncol. 2022 Oct 12:JCO2201408. doi: 10.1200/JCO.22.01408.
    >> Share

  52. HARRINGTON KJ, Burtness B, Greil R, Soulieres D, et al
    Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
    J Clin Oncol. 2022 Oct 11:JCO2102508. doi: 10.1200/JCO.21.02508.
    >> Share

    August 2022
  53. MCLEOD DSA, Bedno SA, Cooper DS, Hutfless SM, et al
    Pre-existing Thyroid Autoimmunity and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study of US Active-Duty Personnel.
    J Clin Oncol. 2022;40:2578-2587.
    >> Share

  54. MARON SB, Moya S, Morano F, Emmett MJ, et al
    Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    J Clin Oncol. 2022;40:2458-2467.
    >> Share

    July 2022
  55. PATEL MA, Kratz JD, Lubner SJ, Loconte NK, et al
    Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102500. doi: 10.1200/JCO.21.02500.
    >> Share

  56. PRICE JM, Mistry HB, Betts G, Cheadle EJ, et al
    Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:2203-2212.
    >> Share

    June 2022
  57. ZHANG Y, Chen L, Hu GQ, Zhang N, et al
    Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2022 Jun 16:JCO2200327. doi: 10.1200/JCO.22.00327.
    >> Share

  58. NORONHA V, Patil VM, Menon N, Prabhash K, et al
    Change in Pattern of Failure in Head and Neck Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200598. doi: 10.1200/JCO.22.00598.
    >> Share

  59. BROSE MS, Pryma DA, Newbold KL
    Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.
    J Clin Oncol. 2022;40:1847-1849.
    >> Share

  60. HO AL, Dedecjus M, Wirth LJ, Tuttle RM, et al
    Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
    J Clin Oncol. 2022;40:1870-1878.
    >> Share

    May 2022
  61. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Should Sentinel Lymph Node Biopsy Be Considered the New Standard of Care for Early-Stage Clinically Node-Negative Oral Squamous Cell Carcinoma?
    J Clin Oncol. 2022;40:1706-1709.
    >> Share

  62. MCDONALD AM, Lindeman B, Bahl D
    Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance.
    J Clin Oncol. 2022;40:1396-1399.
    >> Share

  63. PASQUAL E, Schonfeld S, Morton LM, Villoing D, et al
    Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    J Clin Oncol. 2022;40:1439-1449.
    >> Share

    April 2022
  64. HAYES DN, Gleysteen JP, Schwartz DL
    For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting.
    J Clin Oncol. 2022 Apr 21:JCO2200274. doi: 10.1200/JCO.22.00274.
    >> Share

  65. SHEN L, Kato K, Kim SB, Ajani JA, et al
    Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    J Clin Oncol. 2022 Apr 20:JCO2101926. doi: 10.1200/JCO.21.01926.
    >> Share

  66. FRANCO AT, Ricarte-Filho JC, Isaza A, Jones Z, et al
    Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.
    J Clin Oncol. 2022;40:1081-1090.
    >> Share

  67. FERRIS RL, Burtness B, Flamand Y
    Reply to A.S. Garden.
    J Clin Oncol. 2022;40:1133-1134.
    >> Share

  68. FAGIN JA
    Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer.
    J Clin Oncol. 2022;40:1124-1126.
    >> Share

    March 2022
  69. BURTNESS B, Rischin D, Greil R, Soulieres D, et al
    Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
    J Clin Oncol. 2022 Mar 25:JCO2102198. doi: 10.1200/JCO.21.02198.
    >> Share

  70. MOWERY YM, Salama JK
    Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:814-817.
    >> Share

  71. NICHOLS AC, Theurer J, Prisman E, Read N, et al
    Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial.
    J Clin Oncol. 2022;40:866-875.
    >> Share

  72. KIYOTA N, Tahara M, Mizusawa J, Kodaira T, et al
    Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 1:JCO2101293. doi: 10.1200/JCO.21.01293.
    >> Share

    February 2022
  73. NG WT, Chua MLK, Lee AWM
    Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?
    J Clin Oncol. 2022 Feb 25:JCO2200099. doi: 10.1200/JCO.22.00099.
    >> Share

  74. GARDEN AS
    Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022 Feb 16:JCO2102630. doi: 10.1200/JCO.21.02630.
    >> Share

  75. ZHAO JJ, Yap DWT, Chan YH, Tan BKJ, et al
    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    J Clin Oncol. 2022;40:392-402.
    >> Share

    January 2022
  76. CHAUKAR D, Prabash K, Rane P, Patil VM, et al
    Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.
    J Clin Oncol. 2022;40:272-281.
    >> Share

  77. MCDOWELL L, Magarey MJR, Rischin D
    Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:114-117.
    >> Share

  78. FERRIS RL, Flamand Y, Weinstein GS, Li S, et al
    Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    J Clin Oncol. 2022;40:138-149.
    >> Share

  79. LI XY, Luo DH, Guo L, Mo HY, et al
    Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
    J Clin Oncol. 2022 Jan 6:JCO2101467. doi: 10.1200/JCO.21.01467.
    >> Share

    December 2021
  80. HO AL
    Androgen Receptor Pathway in Salivary Gland Cancer.
    J Clin Oncol. 2021;39:4069-4072.
    >> Share

  81. LOCATI LD, Cavalieri S, Bergamini C, Resteghini C, et al
    Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.
    J Clin Oncol. 2021;39:4061-4068.
    >> Share

  82. KEILTY D, Khandwala M, Liu ZA, Papaioannou V, et al
    Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children.
    J Clin Oncol. 2021;39:3813-3821.
    >> Share

    November 2021
  83. XU B, Fuchs TL, Ahmadi S, Alghamdi M, et al
    International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
    J Clin Oncol. 2021 Nov 3:JCO2101329. doi: 10.1200/JCO.21.01329.
    >> Share

  84. ADENIS A, Kulkarni AS, Girotto GC, de la Fouchardiere C, et al
    Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    J Clin Oncol. 2021 Nov 3:JCO2100601. doi: 10.1200/JCO.21.00601.
    >> Share

    October 2021
  85. SHAH MA, Hofstetter WL, Kennedy EB
    Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021;39:3182-3184.
    >> Share

    September 2021
  86. POTTGEN C, Nestle U, Hocht S, Stuschke M, et al
    Interactions Between Dose and Volume in Chemoradiotherapy of Esophageal Cancer.
    J Clin Oncol. 2021 Sep 23:JCO2101579. doi: 10.1200/JCO.21.01579.
    >> Share

    August 2021
  87. KALRA B, Sinha S, Laskar SG
    De-Escalation in HPV: Near Yet Elusive.
    J Clin Oncol. 2021;39:2733-2734.
    >> Share

  88. CMELAK AJ, Ferris RL, Chen AM, Seiwert T, et al
    Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?
    J Clin Oncol. 2021;39:2732-2733.
    >> Share

  89. HONG S, Zhang Y, Yu G, Peng P, et al
    Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    J Clin Oncol. 2021 Aug 11:JCO2100396. doi: 10.1200/JCO.21.00396.
    >> Share

  90. LI B, Chen H
    The Best Surgery Should Be Applied for Locally Advanced Esophageal Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101340. doi: 10.1200/JCO.21.01340.
    >> Share

    June 2021
  91. GEIGER JL, Ismaila N, Beadle B, Caudell JJ, et al
    Management of Salivary Gland Malignancy: ASCO Guideline.
    J Clin Oncol. 2021;39:1909-1941.
    >> Share

  92. HULSHOF MCCM, Geijsen ED, Rozema T, Oppedijk V, et al
    Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
    J Clin Oncol. 2021 Jun 8:JCO2003697. doi: 10.1200/JCO.20.03697.
    >> Share

  93. GOODMAN KA, Ou FS, Hall NC, Bekaii-Saab T, et al
    Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003611. doi: 10.1200/JCO.20.03611.
    >> Share

    May 2021
  94. HIRSHOREN N, Weinberger JM
    Surgical Perspective on Sentinel Node Biopsy for Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2021;39:1598-1599.
    >> Share

  95. LIU MA, Hsu WT, Johnstone C, Chang A, et al
    Interpreting the Clinical Utility of Early Interdisciplinary Supportive Care for Untreated Metastatic Esophageal Cancer.
    J Clin Oncol. 2021 May 7:JCO2100122. doi: 10.1200/JCO.21.00122.
    >> Share

  96. YOKOYAMA K, Ishiki H
    Questions Regarding Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer.
    J Clin Oncol. 2021 May 5:JCO2100456. doi: 10.1200/JCO.21.00456.
    >> Share

    April 2021
  97. EYCK BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, et al
    Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
    J Clin Oncol. 2021 Apr 23:JCO2003614. doi: 10.1200/JCO.20.03614.
    >> Share

  98. PEARSON AT, Vokes EE
    Is This the Dawn of Precision Oncology in Head and Neck Cancer?
    J Clin Oncol. 2021 Apr 20:JCO2100569. doi: 10.1200/JCO.21.00569.
    >> Share

  99. HASEGAWA Y, Tsukahara K, Yoshimoto S, Miura K, et al
    Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.
    J Clin Oncol. 2021 Apr 20:JCO2003637. doi: 10.1200/JCO.20.03637.
    >> Share

  100. MINAMI H, Kiyota N, Omori T
    Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?
    J Clin Oncol. 2021 Apr 12:JCO2003262. doi: 10.1200/JCO.20.03262.
    >> Share

    March 2021
  101. CHUNDURY A, Kim S
    Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?
    J Clin Oncol. 2021;39:947-949.
    >> Share

  102. YOM SS, Torres-Saavedra P, Caudell JJ, Waldron JN, et al
    Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    J Clin Oncol. 2021;39:956-965.
    >> Share

    January 2021
  103. GEBRE-MEDHIN M, Brun E, Engstrom P, Haugen Cange H, et al
    ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
    J Clin Oncol. 2021;39:38-47.
    >> Share

  104. SEIWERT TY, Kiess AP
    Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1.
    J Clin Oncol. 2021;39:1-3.
    >> Share

  105. WIJNHOVEN BPL, Lagarde SM
    Minimally Invasive Esophagectomy: Time to Reflect on Contemporary Outcomes.
    J Clin Oncol. 2021;39:90-91.
    >> Share

  106. NUYTENS F, Voron T, Piessen G
    Hybrid Minimally Invasive Esophagectomy to the Rescue: A Valid Alternative for Phased Dissemination of TMIE?
    J Clin Oncol. 2021;39:91-92.
    >> Share

    December 2020
  107. GARREL R, Poissonnet G, Moya Plana A, Fakhry N, et al
    Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2020;38:4010-4018.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016